Prof. Wai-Lung Ng uses synthetic chemistry, molecular & cellular biology, and computational tools to develop novel bioactive molecules for the treatment of cancers and diabetes. In particular, our team will use an integrated chemical biology approach to create therapeutic small-molecules for the notoriously “undruggable” targets.
Prof. Kenneth To exploits the use of specific inhibitors of multidrug resistance (MDR) transporters and epigenetic drugs to overcome cancer drug resistance and to improve the efficacy of chemotherapy. MDR transporters also limit the penetration of drugs into several body compartments such as the brain. Therefore, these inhibitors may also potentiate drug efficacy for difficult-to-treat diseases including brain cancer. In recent years, his team has also successfully repurposed non-oncology drugs to overcome resistance to targeted anticancer drugs in the treatment of lung cancer.
See publications (1, 2, 3, 4, 5, 6, 7, 8, 9)
Prof. Xiaoyu Yan uses mathematical modeling and simulation to understand the relationships between exposure (pharmacokinetics) and response (pharmacodynamics). This knowledge is important to select the appropriate dosing regimen for new drugs during clinical development.
See publications (1, 2, 3, 4, 5, 6)
Prof. Joan Zuo tests new drugs to treat CNS diseases and bacterial infections. Prof. Zuo studies the biopharmaceutics and pharmacokinetic characteristics of a series of drug analogs and established a biopharmaceutic/pharmacokinetic-based drug development platform for novel drugs in the above-mentioned therapeutic areas.
See publications (1, 2, 3, 4, 5)